Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer.
about
Understanding and applying pharmacometric modelling and simulation in clinical practice and researchReplication Validity of Initial Association Studies: A Comparison between Psychiatry, Neurology and Four Somatic DiseasesData collection in cancer clinical trials: Too much of a good thing?The future of patient-derived tumor xenografts in cancer treatment.Targeted survival improvements in clinical trials: are you an absolutist or relativist?Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods.Why has active immunotherapy not worked in lung cancer?Poor replication validity of biomedical association studies reported by newspapers.Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis.NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.Publication of trials funded by the National Heart, Lung, and Blood Institute.Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.Context-dependent multifunctionality of galectin-1: a challenge for defining the lectin as therapeutic target.Evaluation of tumor size response metrics to predict survival in oncology clinical trials.Multiplicity and replicability: two sides of the same coin.Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.Phase i trials in melanoma: A framework to translate preclinical findings to the clinic.Overcoming Learning Aversion in Evaluating and Managing Uncertain Risks.The development of dendritic cell vaccine-based immunotherapies for glioblastoma.Sample size planning for phase II trials based on success probabilities for phase III.Reply to Gelman, Gaudart, Pericchi: More reasons to revise standards for statistical evidence.Some thoughts on sample size: a Bayesian-frequentist hybrid approach.Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma.Mathematical modeling of efficacy and safety for anticancer drugs clinical development.New drugs and clinical trial design in advanced sarcoma: have we made any progress?Genetically engineered mouse models: future tools to predict clinical trial results in oncology?The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members.Does clinical trial participation improve outcomes in patients with ovarian cancer?
P2860
Q28468334-2F881D31-0300-439C-923E-3DBCAF78C60CQ28597442-7D55D893-D017-4FE8-BF49-E9A850331983Q30650486-629389C7-A033-4DF7-8CD8-276748853ADFQ33361578-82D2AB26-DAC6-4F8C-AF05-BA79684F62A4Q35084155-BE807AF4-F4D1-4B02-B800-95A23443D2CEQ35821903-DCC85497-C97D-471B-BF53-3BBDA31AAAA0Q36207901-9222F079-3523-4171-924E-7D745182F1D5Q36286246-37BE6AAB-7B01-4BEE-AF61-1C84D41FF14EQ36630997-D5A2C042-6C2C-4AFD-9415-9E3D3E24B618Q37590339-477CBE85-AD8A-4925-B9A0-AD8D31546741Q37592322-674AD611-AF69-4233-87A5-7CDB129801FEQ37696668-CB7B6BDD-4527-4977-B668-684AC9B93ADCQ38071660-D9EED67B-417F-4107-932A-4135CE9EE0ABQ38178093-67F284C9-E54B-4FE5-8405-0AF620AFB9D0Q38259464-564CEFA3-3D3D-46F8-B5A7-F3958CF672A2Q38737416-8FF964CE-C36A-4C9F-8BB6-B9B354DCDE6BQ38816043-4F32321A-C4C0-4A37-AABE-333B8276C305Q38950855-D570D432-6DD4-48E2-B8D9-0E70A2278E6FQ38990679-74AA1509-4DEF-4E01-AC6F-4378B12D85E3Q40493753-4BFE7E3D-EED3-44D9-BC9D-930D9FA64FC3Q42576982-0AE1A62B-71BE-459C-9A65-B191023C9189Q44027568-DEBE4493-89CC-476D-957D-6181F9FFC76EQ47655431-205D94FF-CAEA-4CE0-84C6-08F8E071B6E4Q47663303-E52E78D0-5065-46BB-A0D1-A5B8FACB1B78Q51395236-D0E8C758-9BE9-4ADF-AA0B-6AAE8A833A81Q51427440-BA1190BC-0589-4AA4-B461-A624D69830D5Q53662464-ECB0C559-9B9D-4EDE-9A73-E5710B71A79EQ54912094-C9FF719D-4F0C-47AA-B3EB-9F060F90C8E5
P2860
Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Assumptions of expected benefi ...... ystemic treatments for cancer.
@en
type
label
Assumptions of expected benefi ...... ystemic treatments for cancer.
@en
prefLabel
Assumptions of expected benefi ...... ystemic treatments for cancer.
@en
P2093
P356
P1476
Assumptions of expected benefi ...... ystemic treatments for cancer.
@en
P2093
Benoit You
Eric X Chen
Gregory R Pond
P304
P356
10.1093/JNCI/DJS141
P407
P577
2012-04-06T00:00:00Z